IBTA e-News June 2018 released

By 1st July 2018IBTA News
[30 June 2018] The IBTA's monthly e-News has now been released and has been emailed to all subscribers. To sign up to receive your copy, click here.

You can read the IBTA e-News June 2018 edition in full online here.

Some of the highlights from this month's monthly round-up:

  • The Childhood Cancer Survivorship Treatment Access and Research (STAR) Act was signed into US law on June 5, 2018, which is designed to expand opportunities for childhood cancer research, improve childhood cancer surveillance, improve quality of life for childhood cancer survivors, and ensure paediatric expertise at the US National Institutes of Health (NIH).
  • The inaugural conference of SNOSSA (the Society for NeuroOncology Sub-Saharan Africa) will take place on 22-23 July 2018 at the Transcorp Hilton Hotel, Abuja, Nigeria - a direct result of last year’s Sub-Saharan Africa Neuro-Oncology Collaborative (S-SANOC) planning meeting in London.
  • Interim findings from a phase 3 study of DCVax-L in addition to standard therapy have been published in the Journal of Translational Medicine, reporting that: “Addition of DCVax-L to standard therapy is feasible and safe in glioblastoma patients, and may extend survival.”
  • Combination therapy for glioblastoma has resulted in longer survival but a study of 125 glioblastoma patients, published in the Journal of Neurosurgery, found that only a minority of patients resumed work, mostly on a part-time basis.
  • Data from a phase 2 clinical trial in relapsed/refractory glioblastoma has shown that treatment with a new immunotherapy (SL-701), with or without bevacizumab (Avastin), was well-tolerated and demonstrated anti-tumour activity.
  • Ibrutinib, a drug used for lymphoma and leukaemia, has been found to slow glioblastoma growth and increase sensitivity to radiotherapy, according to preclinical findings published in Science Translational Medicine.
  • Research has reported that advanced MRI—aided by artificial intelligence — classifies brain tumours based on mutation status, decreasing diagnostic uncertainty
  • News agencies have reported that 35-year-old Dr Claire Karekezi, a survivor of the Rwandan genocide, will return to her home country to become the nation's first and only female neurosurgeon.

Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 6,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.

To see an archive of existing e-News issues, click here.

Subscribe to IBTA's e-News!